NCCN Guidelines® for Breast Cancer Updated for Lymphedema

Recommendations align with protocols outlined in ImpediMed's Lymphedema Prevention Program

News provided by

Feb 13, 2020, 08:00 ET

CARLSBAD, Calif., and BRISBANE, Australia, Feb. 13, 2020 /PRNewswire/ -- ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), is pleased to report that the NCCN Clinical Practice Guidelines for Breast Cancer (NCCN Guidelines®) were updated with new recommendations for early detection and diagnosis of lymphedema to achieve optimal management. Additionally, healthcare providers are now encouraged to consider pretreatment baseline measurements for patients with lymphedema risk factors.

Richard Carreon, Managing Director and CEO of ImpediMed, stated, "The medical community recognizes the impact of lymphedema on cancer survivors, and the updated NCCN Guidelines® correlate to ImpediMed's established Lymphedema Prevention Program (LPP) protocols. Implementing of the Test, Trigger, Treat™ protocols using the SOZO® device enables providers to comply with the updated guidelines and provide the best care cancer survivors and other patients at risk of lymphedema."

Information about LPP, as well lymphedema education and prevention information can be found at preventlymphedema.com.

The NCCN Guidelines update follows a request by Vanderbilt University School of Nursing, Lymphatic Education and Research Network (LE&RN), and the American Society of Breast Surgeons Foundation to add language recommending establishing a surveillance program with BIS to detect subclinical breast cancer-related lymphedema (BCRL) and initiate early intervention to reduce the need for complete decongestive physiotherapy. A recommendation for pretreatment baseline measurements to facilitate the earliest identification of subclinical lymphedema was also requested.

The National Comprehensive Care Network® (NCCN®) documents recommendations for diagnostic, treatment, and supportive services provided to cancer patients, which are then referenced by providers and payors when making decisions about care and coverage of oncology patient services.

The minutes from the NCCN Guidelines for Breast Cancer Annual Meeting held on August 15, 2019, can be found at https://www.nccn.org/disclosures/transparency.aspx. The full guidelines are available to registered viewers.

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Media Contact:
Ned Berkowitz
Russo Partners
(646) 942-5629
[email protected]

SOURCE ImpediMed